Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease

Available cholinergic drugs for treating Alzheimer’s disease (AD) provide modest symptomatic benefit. We hypothesized that co-administration of a peripheral anticholinergic to reduce dose-limiting adverse effects (AEs) would enable the safe/tolerable use of higher cholinesterase inhibitor doses and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chase, Thomas N., Farlow, Martin R., Clarence-Smith, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398986/
https://www.ncbi.nlm.nih.gov/pubmed/28138837
http://dx.doi.org/10.1007/s13311-016-0511-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398986/
https://www.ncbi.nlm.nih.gov/pubmed/28138837
http://dx.doi.org/10.1007/s13311-016-0511-x

Ejemplares similares